Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 21, 2021

US FDA approves Samsung Bioepis and Biogen’s Byooviz

The US Food and Drug Administration (FDA) has approved Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab).

US FDA approves Samsung Bioepis and Biogen’s Byooviz